Clinical Trial Update: Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial sponsored by Neonc Technologies evaluating safety and efficacy of a therapy in recurrent or progressive Grade III/IV IDH1-mutant glio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Snippet

Sponsor: Neonc Technologies, Inc. | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: RECRUITING